tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Mesoblast Limited Announces Quotation of New Securities on ASX

Story Highlights
Mesoblast Limited Announces Quotation of New Securities on ASX

Elevate Your Investing Strategy:

Mesoblast Limited ( (AU:MSB) ) has provided an announcement.

Mesoblast Limited has announced the application for the quotation of 2,185,000 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme and reflects the company’s ongoing efforts to enhance its market presence and operational capabilities.

The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.

More about Mesoblast Limited

Mesoblast Limited is a biotechnology company that specializes in developing cellular medicines. The company focuses on innovative therapies for inflammatory diseases, cardiovascular diseases, and back pain, aiming to address unmet medical needs in these areas.

YTD Price Performance: -46.61%

Average Trading Volume: 5,353,171

Technical Sentiment Signal: Hold

Current Market Cap: A$2.11B

See more data about MSB stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1